Remy Cointreau (RCO)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 52.15 |
|---|---|
| 52-week range | 34.24 – 52.45 |
| Return, 1 month / 3 months | +20.4% / +19.9% |
| Return, 1 year / 3 years | +6.8% / −53.9% |
| Trend | Uptrend |
| RSI (14) | 74 |
| Volatility (1 year) | 36.6% |
| Worst drawdown (1 year) | -25.7% |
| Average daily value traded | 2.63M EUR |
| Dividend yield | 1.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Rémy Cointreau is a French spirits company based in Paris. It produces and markets cognac through its Rémy Martin house, including the Louis XIII range, and makes the orange liqueur Cointreau. Its portfolio also includes other spirits such as Mount Gay rum, Metaxa and brandies, along with single malt whiskies. The company sells its brands to consumers and distributors in markets around the world, with a strong presence in travel retail and hospitality as well as in shops.
The shares are listed on the Euronext Paris in France under the code RCO, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Remy Cointreau (RCO) trades on the Euronext Paris in France. It last closed at EUR 52.15 on 23 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 53 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 6.8% and over the last three months it rose 19.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 93 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.6% | ||
| From 52-week high | 0.0% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 19.9% | ||
| 6-month return | 30.6% | ||
| 12-month return, skipping the last month | -11.4% | ||
| Stability (higher is calmer) | 62 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 36.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.7% | ||
| Liquidity | 85 · Strong | Trades actively. | |
| Average daily value traded | 2.63M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 39 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.9% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.2% |
|---|---|
| 1 month | +20.4% |
| 3 months | +19.9% |
| 6 months | +30.6% |
| 1 year | +6.8% |
| 3 years | −53.9% |
| 5 years | −67.1% |
Signals
| 50-day / 200-day average | 44.94 / 41.86 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.67 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 28 Jul 2026 | EUR 0.2500 |
| 27 Jul 2026 | EUR 0.7500 |
| 28 Jul 2025 | EUR 1.0000 |
| 24 Jul 2024 | EUR 2.0000 |
| 28 Sep 2023 | EUR 3.0000 |
| 27 Jul 2022 | EUR 2.8500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.